Drug class
Interleukin-23 receptor (IL-23R) antagonist; oral peptide immunomodulator
Mechanism of action
Selectively binds the IL-23 receptor and antagonises IL-23 binding, inhibiting IL-23/IL-23R-dependent release of pro-inflammatory cytokines involved in plaque psoriasis pathogenesis.
General use cases
- Treatment of moderate-to-severe plaque psoriasis in adults and paediatric patients aged 12 years and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy under the US FDA ICOTYDE indication (approved 17 March 2026); the hydrochloride form is a salt of the same active peptide.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
